Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial

Y. Gao, B. Weenink, M. J. van den Bent, L. Erdem-Eraslan, J. M. Kros, P. A. E. Sillevis Smitt, K. Hoang-Xuan, A. A. Brandes, M. Vos, F. Dhermain, R. Enting, G. F. Ryan, O. Chinot, M. Ben Hassel, M. E. van Linde, W. P. Mason, J. M. M. Gijtenbeek, C. Balana, A. von Deimling, Th GorliaR. Stupp, M. E. Hegi, B. G. Baumert, P. J. French*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

16 Citations (Web of Science)
Original languageEnglish
Pages (from-to)168-178
Number of pages11
JournalEuropean Journal of Cancer
Volume94
DOIs
Publication statusPublished - 1 May 2018

Keywords

  • Low grade glioma
  • Intrinsic subtype
  • Pilocytic astrocytoma
  • Gene expression profiling
  • Immunophenotype
  • BELOB
  • OLIGODENDROGLIAL BRAIN-TUMORS
  • CENTRAL-NERVOUS-SYSTEM
  • PHASE-III TRIAL
  • RANDOMIZED-TRIAL
  • VINCRISTINE CHEMOTHERAPY
  • PILOCYTIC ASTROCYTOMAS
  • ADJUVANT PROCARBAZINE
  • RADIATION-THERAPY
  • EORTC 22033-26033
  • MGMT METHYLATION

Cite this